---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-319170"
form_type: "8-K/A"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:18:54.681656+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MannKind pro forma shows $36.1M net loss for H1 2025 post-scPharma acquisition

## Summary
- Acquired scPharma for $5.35/share cash plus CVR (up to $1.00/share); total consideration $396.4M cash.
- Pro forma combined net loss of $36.1M for six months ended June 30, 2025 vs. MannKind standalone net income of $13.8M.
- Pro forma combined net loss of $96.9M for year ended Dec 31, 2024 (MannKind $27.6M income, scPharma $85.1M loss).
- Acquisition financed via $325M term loan (initial $75M, DDTL $75M, incremental $175M) at SOFR + 4.75% margin.
- Pro forma total assets $765.8M, total liabilities $832.6M, stockholders' deficit $66.8M as of June 30, 2025.

## SEC filing metadata
- accession: 0001193125-25-319170
- form_type: 8-K/A
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000119312525319170/0001193125-25-319170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000119312525319170/mnkd-20251007.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-319170
- JSON: https://secwatch.observer/filing/0001193125-25-319170.json
- Plain text: https://secwatch.observer/filing/0001193125-25-319170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.